β-alanine in the Treatment of Advanced Hepatocellular Carcinoma

This study is a prospective, randomized controlled study on nutritional support and metabolic regulation. It assesses the safety, compliance, and improvement of metabolic/physical-related indicators when using β-alanine within the specified dose range as dietary supplementation, in addition to the standard first-line treatment. The anti-tumor efficacy (ORR, PFS, OS) is the exploratory endpoint.

Trial Details

NCT ID
NCT07317414
Phase
PHASE2
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Atezolizumab combined with bevacizumab combined with β- alanine
  • Atezolizumab combined with bevacizumab
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

  • The subjects voluntarily participated in the study and agreed to sign the written informed consent. They had good compliance, cooperated with the f…
  • Patients diagnosed by imaging and histological examinations as having unresectable, recurrent, locally advanced or metastatic liver cell carcinoma,…
  • With measurable lesions (according to the RECIST 1.1 standard, non-lymph node lesions have a CT scan long diameter of ≥ 10 mm, and lymph node lesio…
  • At least 4 weeks prior to the baseline assessment, radical surgery/local treatment was not suitable, or disease progression occurred thereafter. Th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →